Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021
May 19, 2021 07:00 ET
|
Trevena Inc.
-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care -- CHESTERBROOK, Pa., May 19, 2021 (GLOBE NEWSWIRE) --...
Trevena Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting
May 12, 2021 07:00 ET
|
Trevena Inc.
-- Elderly and obese patients receiving OLINVYK are not at increased risk for respiratory depression, compared to younger and non-obese patients, based on exploratory analysis -- CHESTERBROOK, Pa.,...
Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial
May 06, 2021 07:03 ET
|
Trevena Inc.
-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS TRV027 to be dosed in ~300 COVID-19 patients -- CHESTERBROOK, Pa., May 06,...
Trevena Reports First Quarter 2021 Results
May 06, 2021 07:00 ET
|
Trevena Inc.
-- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and...
Trevena to Release First Quarter 2021 Financial Results on May 6, 2021
May 05, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum
April 29, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central...
Trevena Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 Patients
April 21, 2021 07:00 ET
|
Trevena Inc.
-- REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19 Interim review of Imperial College London TRV027 study data...
Trevena, Inc. Announces Presentations of OLINVYK™ Health Economic Models at AMCP 2021 Annual Meeting
April 15, 2021 07:30 ET
|
Trevena Inc.
-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care -- CHESTERBROOK, Pa., April 15, 2021 (GLOBE NEWSWIRE) --...
Trevena, Inc. Appoints Marvin H. Johnson, Jr. to Board of Directors
March 18, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results
March 09, 2021 07:00 ET
|
Trevena Inc.
-- OLINVYK™ approved in U.S.; customer-facing teams now fully deployed Primary study completion for TRV027 in COVID-19 patients expected in 1H 2021 IND for TRV045 (S1P1 receptor modulator) on track...